Skip to main content
Premium Trial:

Request an Annual Quote

Teva Exercises Option on Compugen Biomarkers

NEW YORK (GenomeWeb News) – Compugen today said that Teva Pharmaceutical industries has exercised its option to utilize in its research activities a combination of biomarkers discovered by the firm for early detection of drug-induced nephrotoxicity.

The biomarkers were discovered under a collaboration between the two firms in 2007. Compugen used its computational tools, discovery engines, and nucleic acid testing platforms, as well as data from Teva, in a preclinical study.

Teva has a royalty-free right to use the biomarkers for internal research and development efforts, while Compugen retained the commercialization rights for licensing such markers to other firms and rights to use the biomarkers internally. Compugen noted that it intends to commercially launch the biomarkers through licensing arrangements during the second half of this year.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.